IVA · Inventiva S.A.

This executive leadership expansion signals a deliberate organizational pivot toward late-stage clinical execution and commercial preparedness. The appointments directly align with the imminent Q4 2026 top-line readout of the NATiV3 Phase 3 trial for lanifibranor—the company’s sole late-stage asset in metabolic dysfunction-associated steatohepatitis (MASH). Malkomes’ background includes guiding CureVac through acquisition by BioNTech and preparing Cardior for capital markets before its acquisition by Novo Nordisk, suggesting expertise in transaction-readiness and investor-facing financial strategy. Coles’ dual tenure as Inventiva’s General Counsel—including during its Nasdaq listing—and her role in Pfizer’s option-to-purchase deal with Vivet underscore deep familiarity with cross-border licensing, regulatory engagement, and public company governance. Herbster’s track record spans people strategy through Sage’s acquisition by Supernus and global R&D leadership at Merck KGaA and Biogen, indicating capacity to scale talent infrastructure for commercial launch. Critically, the retention of Jean Volatier as EVP Finance & CSR and Nathalie Harroy ensures continuity of foundational operational knowledge while enabling strategic delegation. For investors, this is not routine succession but a targeted build-out timed to de-risk the next 12–18 months: successful Phase 3 data could trigger regulatory submissions (e.g., FDA NDA, EMA MAA) and commercial planning, all of which require integrated finance, legal, and human capital capabilities. Given Inventiva’s status as a clinical-stage company with no approved products or revenue, the credibility and execution capacity of this leadership cohort materially influence near-term valuation drivers—particularly confidence in data integrity, regulatory pathway navigation, and commercial feasibility.